You are here

Aerobika* Oscillating Positive Expiratory Pressure Therapy System

Aerobika device

The exacerbating facts...

During an exacerbation, airways are compromised by inflammation, mucus buildup, and dynamic lung hyperinflation.1

Delaying recovery beyond 30 days places patients at risk for further airway deterioration and recurrent exacerbations.2

 

Post-exacerbation care...

According to guidelines, the goal is to minimize the impact of the current exacerbation and to prevent the development of subsequent exacerbations.3

 

Real world study results show that the Aerobika* device is clinically proven to reduce exacerbations. When used in addition to usual COPD treatment, the Aerobika* device has been shown to reduce hospital re-admittance by 28% in the first 30 days after exacerbation.4 It is drug-free and easy-to-use with no side-effects or drug interactions.

 

Want to learn more? Contact us today to learn more about the Aerobika* device.

 

 

How the Aerobika* OPEP Device Works

QUICK FACTS
  • The Lung Association believes that the Aerobika* OPEP device is a drug-free way to open airways, clear mucus and reduce breathlessness.

  • Chronic cough and sputum production has been linked to premature death and increased occurrence of exacerbations5

  • 50% of COPD hospital admissions are associated with bacterial infections6,7

  • 54% of deaths occurred in patients exhibiting mucus hypersecretion versus 28% of those without8

  • Subjects with COPD and mucus hypersecretion are more likely to die from pulmonary infections8

  • Chronic cough and sputum production has been linked to premature death and increased occurrence of exacerbations5

 

In a patient satisfaction survey, 97% of respondents said they would continue to use the Aerobika* device.†9

 

INSTRUCTIONS

>> Download Full Instructions (PDF)

 

For the critical 30 days after an exacerbation administer for 10 minutes, twice daily.

 

For ongoing airway maintenance continue to administer at least once a day.

 

The Aerobika* device is drug-free and should be used as an add-on to usual COPD treatment.

ADDITIONAL INFORMATION

Resources for Aerobika

Resources

Download resources related to Aerobika*.

Patient satisfaction survey given to 504 patients after ≥3 weeks of twice-daily use of the Aerobika* device.
1 O’Donnell DE, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J. 2007;14(Suppl B):5B-32B.
2 Shah T, et al. COPD Readmissions: Addressing COPD in the Era of Value-Based Healthcare. Chest. 2016 May 7. doi: 10.1016/j.chest.2016.05.002. [Epub ahead of print]
3 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015.
4Burudpakdee C, et al. A Real World Study of Aerobika* OPEP in Chronic Obstructive Pulmonary Disease Patients, Investigating Hospital Related Exacerbations. Manuscript.
5 Prescott, E., P. Lange, and J. Vestbo. “Chronic mucus hypersecretion in COPD and death from pulmonary infection.” European Respiratory Journal 8.8 (1995): 1333-1338.
6 Burgel, P. R., and C. Martin. “Mucus hypersecretion in COPD: should we only rely on symptoms?.” European Respiratory Review 19.116 (2010): 94-96.
7 Tesfaigzi, Yohannes, Paula Meek, and Suzanne Lareau. “Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion.” Clinical and Applied Immunology Reviews 6.1 (2006): 21-36.
8 Groenewegen, Karin H., and Emiel FM Wouters. “Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study.” Respiratory medicine 97.7 (2003): 770-777.

9 Harkness H, et al. Survey of Patients Using an Oscillating Positive Expiratory Pressure Device Indicates Improvement in Well-Being and Compliance to Therapy. Presented at: Canadian Respiratory Conference. April 23–25, 2015. Ottawa, Ontario.